- Home
- CMMB vs ALCE Comparison
CMMB vs ALCE Comparison
Compare CMMB & ALCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- ALCE
- Stock Information
- Founded
- CMMB 2004
- ALCE 2019
- Country
- CMMB Israel
- ALCE United States
- Employees
- CMMB N/A
- ALCE N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- ALCE Power Generation
- Sector
- CMMB Health Care
- ALCE Utilities
- Exchange
- CMMB Nasdaq
- ALCE Nasdaq
- Market Cap
- CMMB 20.9M
- ALCE 13.9M
- IPO Year
- CMMB N/A
- ALCE N/A
- Fundamental
- Price
- CMMB $1.13
- ALCE $2.64
- Analyst Decision
- CMMB Strong Buy
- ALCE
- Analyst Count
- CMMB 3
- ALCE 0
- Target Price
- CMMB $5.67
- ALCE N/A
- AVG Volume (30 Days)
- CMMB 154.2K
- ALCE 366.2K
- Earning Date
- CMMB 11-07-2024
- ALCE 11-15-2024
- Dividend Yield
- CMMB N/A
- ALCE N/A
- EPS Growth
- CMMB N/A
- ALCE N/A
- EPS
- CMMB N/A
- ALCE N/A
- Revenue
- CMMB N/A
- ALCE N/A
- Revenue This Year
- CMMB N/A
- ALCE N/A
- Revenue Next Year
- CMMB N/A
- ALCE N/A
- P/E Ratio
- CMMB N/A
- ALCE N/A
- Revenue Growth
- CMMB N/A
- ALCE N/A
- 52 Week Low
- CMMB $0.42
- ALCE $2.17
- 52 Week High
- CMMB $2.55
- ALCE $62.75
- Technical
- Relative Strength Index (RSI)
- CMMB 28.21
- ALCE 25.58
- Support Level
- CMMB $1.29
- ALCE $2.17
- Resistance Level
- CMMB $1.59
- ALCE $8.00
- Average True Range (ATR)
- CMMB 0.17
- ALCE 0.72
- MACD
- CMMB -0.06
- ALCE -0.10
- Stochastic Oscillator
- CMMB 4.41
- ALCE 8.06
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
About ALCE Alternus Clean Energy Inc.
Alternus Clean Energy Inc is an international independent clean energy producer. It develops, installs, owns and operates a diverse portfolio of utility-scale solar photovoltaic power stations (PV parks) in Europe and the USA as a long-term owner. The solar parks benefit from long-term government offtake contracts and/or Power Purchase Agreements (PPAs) with investment grade off-takers, plus energy sales to local power grids. It has approximately 8 operating parks, a total of 44 MWp in operation.